4:21 PM
 | 
Apr 13, 2018
 |  BC Extra  |  Company News

Report: Hanmi discontinuing lung cancer drug olmutinib

Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) will discontinue development of olmutinib, which is approved in South Korea for lung cancer, the Korea Biomedical Review reported Friday. Hanmi did not respond to inquiries.

In 2016, Boehringer Ingelheim GmbH (Ingelheim, Germany) returned olmutinib's rights to Hanmi after the Korean Ministry of Food and Drug Safety reported three serious skin reactions, including one fatal case, in clinical trials of the product to treat non-small cell lung cancer (NSCLC) (see BioCentury Extra, Sept. 30, 2016).

The Korea Biomedical Review also reported that Zai Lab Ltd. (NASDAQ:ZLAB) said it would end its deal with Hanmi for Chinese rights to olmutinib. Zai did not respond to inquiries.

Olmutinib is a third-generation EGFR mutation-specific tyrosine kinase inhibitor (TKI).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD